Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Cash & Equivalents (2016 - 2025)

Haemonetics has reported Cash & Equivalents over the past 17 years, most recently at $363.4 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $363.4 million for Q4 2025, up 13.25% from a year ago — trailing twelve months through Dec 2025 was $363.4 million (up 13.25% YoY), and the annual figure for FY2025 was $306.8 million, up 71.57%.
  • Cash & Equivalents for Q4 2025 was $363.4 million at Haemonetics, up from $296.4 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for HAE hit a ceiling of $363.4 million in Q4 2025 and a floor of $173.5 million in Q3 2021.
  • Median Cash & Equivalents over the past 5 years was $272.0 million (2022), compared with a mean of $262.6 million.
  • Biggest five-year swings in Cash & Equivalents: tumbled 37.15% in 2024 and later soared 71.57% in 2025.
  • Haemonetics' Cash & Equivalents stood at $192.4 million in 2021, then increased by 16.41% to $224.0 million in 2022, then decreased by 13.4% to $194.0 million in 2023, then surged by 65.4% to $320.8 million in 2024, then grew by 13.25% to $363.4 million in 2025.
  • The last three reported values for Cash & Equivalents were $363.4 million (Q4 2025), $296.4 million (Q3 2025), and $292.9 million (Q2 2025) per Business Quant data.